Howard Stern TRT: Hypothesized Full Protocol

What Howard Stern Has Said Publicly About TRT

Stern has been candid about testosterone therapy across several episodes of The Howard Stern Show on SiriusXM. He has described fatigue, low libido, and mood changes as the symptoms that led him to seek treatment, and he has mentioned working with a physician who monitors his labs regularly. These disclosures are consistent with a textbook presentation of late-onset hypogonadism.

The Symptoms He Described

Fatigue and diminished drive are the two most commonly reported complaints among men who are ultimately diagnosed with hypogonadism. In a cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism, low serum testosterone was associated with decreased energy, reduced libido, and depressed mood in men over 60 (1). Stern's self-reported experience maps closely to that symptom cluster.

Why Age Matters Here

The prevalence of biochemical hypogonadism increases sharply after age 65. The European Male Aging Study (N=3,369) found that symptomatic androgen deficiency affected approximately 2.1% of men aged 40 to 79, but prevalence rose steeply in the oldest cohort (2). A man in his early 70s presenting with the symptoms Stern described has a meaningful prior probability of clinically low testosterone before a single lab value is drawn.

The Diagnostic Standard His Physician Would Use

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism specifies that diagnosis requires both symptoms consistent with testosterone deficiency and a confirmed low morning total testosterone on at least two separate measurements (3). The guideline states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness." That caution matters because it sets the bar for legitimate treatment. Stern's multi-year, ongoing treatment implies his physician satisfied this diagnostic threshold.

Hypothesized Core Protocol: Testosterone Cypionate

For a man in his early 70s with confirmed symptomatic hypogonadism, testosterone cypionate remains the most widely prescribed injectable ester in the United States. The pharmacokinetic profile is well-characterized: a half-life of approximately 8 days, with peak serum levels at 24 to 72 hours post-injection and a trough at roughly day 7 (4).

Hypothesized Dose and Frequency

A starting dose of 100 mg intramuscularly or subcutaneously every 7 days is consistent with Endocrine Society guidance, which targets a mid-normal range total testosterone of 400 to 700 ng/dL for older adults (3). Some clinicians titrate to 150 mg weekly in men who remain symptomatic below 500 ng/dL. Weekly injections reduce the peak-to-trough swing seen with the older every-two-week protocol and are associated with more stable mood and energy reports in clinical practice.

Hypothesized dose: 100 to 150 mg testosterone cypionate subcutaneously, once weekly.

This is inference based on standard-of-care dosing for his demographic. No confirmed dose has been publicly disclosed by Stern or his physician.

Injection Route Consideration

Subcutaneous injection into abdominal fat has become a common alternative to intramuscular gluteal injection. A 2017 pharmacokinetic study (N=32) published in the Journal of Urology found that subcutaneous testosterone cypionate produced stable serum levels comparable to intramuscular delivery, with less injection-site discomfort (5). Given Stern's reportedly health-conscious approach to his care, subcutaneous self-injection at home is a plausible administration route.

Hypothesized Ancillary: Estradiol Management

Testosterone aromatizes to estradiol. In men on TRT, supraphysiologic estradiol can cause gynecomastia, water retention, and mood instability. Estradiol above 42.6 pg/mL on an ultrasensitive assay is the threshold many TRT-specialized physicians use to initiate an aromatase inhibitor.

Anastrozole as the Standard Adjunct

Anastrozole 0.25 mg to 0.5 mg twice weekly is the most commonly co-prescribed aromatase inhibitor in TRT clinics. The Testosterone Trials (TTrials), a coordinated set of seven double-blind placebo-controlled trials in men 65 and older (N=790 in the sexual function trial), used testosterone gel and monitored estradiol as a secondary endpoint, confirming that estradiol rises proportionally with testosterone supplementation (6). A physician managing a man of Stern's age on weekly cypionate would almost certainly run an ultrasensitive estradiol panel at the 6-week mark.

Hypothesized dose: Anastrozole 0.25 mg orally, twice weekly, titrated by lab.

Why Over-Suppression of Estradiol Is a Risk

Estradiol performs essential functions in men: bone mineral density maintenance, lipid regulation, and cognitive function. The American Urological Association's 2022 guideline notes that estradiol below 20 pg/mL in men on TRT is associated with decreased bone density and increased fracture risk (7). A careful clinician prescribes the lowest anastrozole dose that keeps estradiol in the 20 to 35 pg/mL range, not as low as possible.

Hypothesized Ancillary: hCG or Enclomiphene for Testicular Function

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH secretion. This leads to testicular atrophy and azoospermia in most men within 3 to 6 months of starting TRT. For men who wish to preserve testicular volume or residual fertility, two options are standard.

Human Chorionic Gonadotropin (hCG)

HCG mimics LH and directly stimulates Leydig cells to maintain intratesticular testosterone and testicular size. Doses of 500 to 1,000 IU subcutaneously two to three times per week are used alongside TRT. A 2005 study in the Journal of Clinical Endocrinology and Metabolism (N=29) showed that 500 IU hCG every other day maintained intratesticular testosterone concentrations during exogenous testosterone administration (8).

Enclomiphene as a Newer Option

Enclomiphene citrate, a selective estrogen receptor modulator, stimulates endogenous LH and FSH release by blocking hypothalamic estrogen receptors. It preserves the HPG axis without injections. For a health-conscious patient who prefers fewer injection sites, enclomiphene 12.5 to 25 mg orally daily is a plausible alternative. The FDA has not yet approved enclomiphene as a standalone drug; it is currently prescribed off-label (9).

Hypothesized adjunct: Either hCG 500 IU subcutaneously twice weekly OR enclomiphene 12.5 mg orally daily. This is inference; no public disclosure exists.

Lab Monitoring Protocol a Physician Would Follow

A responsible TRT practice does not prescribe and forget. The Endocrine Society's 2018 guideline specifies monitoring at 3 and 6 months after initiation, then annually (3). The panel below outlines what Stern's physician would most likely order.

Baseline Panel (Before Starting TRT)

• Total testosterone (morning, two separate draws)
• Free testosterone (equilibrium dialysis method)
• LH and FSH
• Estradiol (ultrasensitive LC-MS/MS assay)
• Complete blood count (hematocrit baseline)
• PSA (prostate-specific antigen)
• Comprehensive metabolic panel
• Lipid panel
• SHBG (sex hormone-binding globulin)

Follow-Up Panel at 90 Days

The 90-day draw checks for the two most common adverse effects of TRT: polycythemia (hematocrit above 54%) and PSA rise above 1.4 ng/mL from baseline. A 2020 meta-analysis in JAMA Internal Medicine (N=3,431 across 35 trials) found that testosterone therapy increased hematocrit by a mean of 3.2 percentage points compared with placebo, with a relative risk of polycythemia of 3.69 (10). That finding underscores why the CBC is non-negotiable at every monitoring visit.

PSA Monitoring and Prostate Safety

The relationship between TRT and prostate cancer risk has been studied extensively. The TTrials prostate trial found no significant difference in prostate cancer incidence between testosterone and placebo groups over one year (11). Still, the FDA's prescribing label for testosterone products requires PSA monitoring, and most guidelines recommend urological referral if PSA rises more than 1.4 ng/mL above baseline within 12 months (3).

Cardiovascular Considerations for a Man in His 70s

The FDA issued a safety communication in 2015 requiring all testosterone product labels to carry a warning about possible increased cardiovascular risk (12). This warning was based on observational data and two randomized trials that showed conflicting signals.

What the TRAVERSE Trial Showed

The 2023 TRAVERSE trial (N=5,246 men with hypogonadism and pre-existing cardiovascular disease or high risk) published in the New England Journal of Medicine found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months, with a hazard ratio of 0.96 (95% CI 0.78 to 1.17) (13). This was a landmark finding. The trial did note a higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone arm.

For a man in his early 70s without severe cardiovascular disease, the TRAVERSE data support TRT as reasonably safe from a cardiac standpoint, provided hematocrit and blood pressure are monitored. A physician treating Stern would review this trial and weigh the atrial fibrillation signal carefully.

Blood Pressure and Hematocrit Management

If hematocrit exceeds 54%, standard practice is to reduce the testosterone dose, increase injection frequency to flatten the peak, or perform therapeutic phlebotomy. Blood pressure above 140/90 mmHg warrants antihypertensive co-management before TRT dose escalation.

Thyroid and Other Hormones Stern Has Mentioned

Stern has also referenced thyroid medication and broader hormonal optimization work in interviews. Men on TRT who also have subclinical hypothyroidism may find that thyroid normalization improves the symptomatic response to testosterone, because thyroid hormone regulates SHBG production (14).

Hypothesized Thyroid Component

If Stern's TSH ran above 4.5 mIU/L with symptoms, a physician might prescribe levothyroxine starting at 25 to 50 mcg daily, titrating to a TSH of 1.0 to 2.5 mIU/L. Some functional medicine and longevity-focused practices use combination T4/T3 therapy (levothyroxine plus liothyronine), though the American Thyroid Association does not endorse combination therapy as first-line for most patients.

What This Protocol Would Look Like Week-to-Week

A man following this hypothesized protocol would have a structured weekly routine.

• Sunday evening: Testosterone cypionate 100 to 150 mg subcutaneous injection (abdominal or lateral thigh)
• Monday morning: Anastrozole 0.25 mg oral tablet
• Thursday morning: Anastrozole 0.25 mg oral tablet; hCG 500 IU subcutaneous injection (if using hCG instead of enclomiphene)
• Daily (if enclomiphene): Enclomiphene 12.5 mg oral tablet each morning
• Every 90 days: Full lab panel including total testosterone (drawn at trough, day 7 post-injection), free testosterone, estradiol (ultrasensitive), hematocrit, PSA, lipids, CMP

This structure is not unique to Stern. It reflects a well-run TRT protocol for any man in his age cohort with confirmed hypogonadism. The specific drugs and doses remain hypothesized for Stern specifically.

What Physicians Say About TRT in Men Over 65

The Endocrine Society's guideline authors wrote: "We suggest that clinicians consider offering testosterone therapy to older men with age-related decline in testosterone if they have symptoms and signs of androgen deficiency and consistently low serum testosterone concentrations, after explicit discussion of the uncertain balance of benefits and risks" (3).

That conditional language reflects where the evidence actually stands. TRT in older men improves sexual function, bone mineral density, and lean body mass with reasonable consistency across trials. In the TTrials sexual function cohort, testosterone-treated men showed a mean increase of 2.64 points on the Psychosexual Daily Questionnaire sexual desire domain versus 0.54 points for placebo (P<0.001) (6). Mood and energy improvements are reported but harder to quantify in blinded trials.